Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: The Puzih eye study

Eye (Basingstoke)

Volumn 28, Issue 6, 2014, Pages 705-714

  Huang, E J C ^a,b   Wu, S H ^a,b   Lai, C H ^a,b,c   Kuo, C N ^a,b   Wu, P L ^a,b   Chen, C L ^a,b   Chen, C Y ^a,b   King, Y C ^a   Wu, P C ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHINESE; DEMOGRAPHY; DRUSEN; EYE FUNDUS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SUN EXPOSURE; TAIWAN; WISCONSIN AGE RELATED MACULOPATHY GRADING SYSTEM;

EID: 84928768988     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.55     Document Type: Article

References (17)

1. Wagner H, Barr JT, Zadnik K. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date. Cont Lens Anterior Eye 2007; 30(4): 223-232.
2. Coskunseven E, Jankov 2nd MR, Hafezi F. Contralateral eye study of corneal collagen cross-linking with riboflavin and UVA irradiation in patients with keratoconus. J Refract Surg 2009; 25(4): 371-376.
3. Hersh PS, Greenstein SA, Fry KL. Corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results. J Cataract Refract Surg 37(1): 149-160.
4. Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg 2008; 24(7): S720-S725.
5. Malik NS, Moss SJ, Ahmed N, Furth AJ, Wall RS, Meek KM. Ageing of the human corneal stroma: structural and biochemical changes. Biochim Biophys Acta 1992; 1138(3): 222-228.
6. Davis LJ, Schechtman KB, Wilson BS, Rosenstiel CE, Riley CH, Libassi DP et al. Longitudinal changes in visual acuity in keratoconus. Invest Ophthalmol Vis Sci 2006; 47(2): 489-500.
7. Kymes SM, Walline JJ, Zadnik K, Sterling J, Gordon MO. Changes in the quality-of-life of people with keratoconus. Am J Ophthalmol 2008; 145(4): 611-617.
8. McMahon TT, Szczotka-Flynn L, Barr JT, Anderson RJ, Slaughter ME, Lass JH et al. A new method for grading the severity of keratoconus: the Keratoconus Severity Score (KSS). Cornea 2006; 25(7): 794-800.
9. Koller T, Mrochen M, Seiler T. Complication and failure rates after corneal crosslinking. J Cataract Refract Surg 2009; 35(8): 1358-1362.
10. Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg 2009; 35(4): 621-624.
11. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-ainduced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 2003; 135(5): 620-627.
12. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg 2008; 34(5): 796-801.
13. Herrmann CI, Hammer T, Duncker GI. [Hazeformation (corneal scarring) after cross-linking therapy in keratoconus]. Ophthalmologe 2008; 105(5): 485-487.
14. Mazzotta C, Balestrazzi A, Baiocchi S, Traversi C, Caporossi A. Stromal haze after combined riboflavin-UVA corneal collagen cross-linking in keratoconus: in vivo confocal microscopic evaluation. Clin Experiment Ophthalmol 2007; 35(6): 580-582.
15. Greenstein SA, Fry KL, Bhatt J, Hersh PS. Natural history of corneal haze after collagen crosslinking for keratoconus and corneal ectasia: Scheimpflug and biomicroscopic analysis. J Cataract Refract Surg 36(12): 2105-2114.
16. Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg 2006; 32(5): 837-845.
17. Blackwelder WC. 'Proving the null hypothesis' in clinical trials. Control Clin Trials 1982; 3(4): 345-353.